Twenty-One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain predict treatment response to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
• Current guidelines recommend sequencing EGFR exons 18-21 for identifying these actionable variants.
• Understanding the spectrum of EGFR variants is crucial for optimizing targeted therapy in NSCLC.

Purpose of the Study:

• To identify and characterize novel somatic sequence variants within EGFR exons 18-21 in a cohort of adult Argentinean NSCLC patients.
• To analyze the nature and combinations of these variants, including single amino acid substitutions, deletions, and duplications.
• To investigate previously unreported positions of EGFR kinase domain variants.

Main Methods:

• Somatic DNA sequencing of EGFR exons 18-21 in NSCLC patient samples.
• Classification of identified variants (single amino acid substitutions, deletions, insertions, duplications, and complex cases).
• Physicochemical, sequence, and conformational analyses for characterizing novel variants.

Main Results:

• Identification of 21 novel somatic variants in EGFR exons 18-21 from adult Argentinean NSCLC patients.
• The majority (18) were single amino acid substitutions (SASs), found alone or in complex combinations.
• Discovery of one deletion, one deletion-insertion, one duplication, and two SASs at previously unreported positions.

Conclusions:

• This study reports a significant number of novel EGFR somatic variants in NSCLC patients from Argentina.
• The characterization of these new variants and their combinations deepens our understanding of EGFR alterations in NSCLC.
• Identifying diverse EGFR variants can aid in selecting the most effective TKI therapy for individual patients, improving treatment outcomes.